Oramed Pharmaceuticals Research and Development Expenses 2011-2024 | ORMP

Oramed Pharmaceuticals research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Oramed Pharmaceuticals Research and Development Expenses 2011-2024 | ORMP

Oramed Pharmaceuticals research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$200B
Stryker (SYK)$141B
Boston Scientific (BSX)$128B
Medtronic (MDT)$113B
EssilorLuxottica (ESLOY)$112.7B
Lonza Group Ag (LZAGY)$45.3B
Haleon (HLN)$43.5B
GE HealthCare Technologies (GEHC)$40.4B
ResMed (RMD)$36.5B
Terumo (TRUMY)$30.3B
Koninklijke Philips (PHG)$25.9B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$18.4B
Insulet (PODD)$17.2B
Smith & Nephew SNATS (SNN)$10.8B
Bio-Rad Laboratories (BIO)$10.4B
BellRing Brands (BRBR)$8.9B
Demant (WILYY)$8.4B
Lantheus Holdings (LNTH)$6.1B
Haemonetics (HAE)$4.4B
ICU Medical (ICUI)$4.4B
TG Therapeutics (TGTX)$4.3B
Prestige Consumer Healthcare (PBH)$4B
Envista Holdings (NVST)$3.7B
Perrigo (PRGO)$3.7B
Neogen (NEOG)$3.4B
Agios Pharmaceuticals (AGIO)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.9B
QuidelOrtho (QDEL)$2.6B